{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-24-000005","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.602407+00:00","generated_at":"2026-06-06T02:06:11.488750+00:00","sec_items":["1.01","1.02","2.03","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Bio-Rad enters $200M credit facility; CEO Schwartz appointed interim CFO after Daskal departure","bullets":["New $200M revolving credit facility with Wells Fargo, matures Feb 13, 2029; replaces prior $200M facility.","CFO Ilan Daskal resigned effective Nov 6, 2023; CEO Norman Schwartz appointed interim principal financial officer on Feb 9, 2024.","Facility includes leverage ratio covenant of 3.50x; interest rates based on SOFR plus margin.","Outstanding obligations under prior credit agreement repaid in full on Feb 14, 2024 with no penalties."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-24-000005","json":"https://secwatch.observer/filing/0000012208-24-000005.json","markdown":"https://secwatch.observer/filing/0000012208-24-000005.md","text":"https://secwatch.observer/filing/0000012208-24-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000005/0000012208-24-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000005/bio-20240209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:06:11.488750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56aab68fb9df156e04f015a8f730583ee722d2af","claim":"BIO-RAD LABORATORIES, INC. incurred revolving credit of $200,000,000 with Wells Fargo Bank, National Association, as agent at Term SOFR plus 0.10% per annum plus the Applicable Margin maturing February 13, 2029.","evidence_excerpt":"all commitments thereunder. No penalties were due in connection with such repayments. Borrowings under the Revolving Credit Agreement are permitted up to a maximum amount of $200,000,000 on a revolving basis, including up to $25,000,000 of letters of credit. Borrowings of revolving loans may be made, at the Borrowers’ election, in U.S. dollars, Euros, Swiss","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000005/0000012208-24-000005-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"revolving credit"},{"label":"Principal","value":"$200,000,000"},{"label":"Counterparty","value":"Wells Fargo Bank, National Association, as agent"},{"label":"Rate","value":"Term SOFR plus 0.10% per annum plus the Applicable Margin"},{"label":"Maturity","value":"February 13, 2029"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"692be354a6","claim":"Norman Schwartz was appointed as principal financial officer at BIO-RAD LABORATORIES, INC..","evidence_excerpt":"On February 9, 2024, the Company’s board of directors appointed Norman Schwartz, the Company’s President and Chief Executive Officer and the Chairman of the Board, as the Company’s principal financial officer until a permanent replacement for Mr. Daskal has been appointed.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000005/0000012208-24-000005-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal financial officer"}],"fact_type":"executive_change"},{"claim_id":"af6aa0aa46","claim":"Ilan Daskal resigned as Executive Vice-President, Chief Financial Officer at BIO-RAD LABORATORIES, INC..","evidence_excerpt":"Ilan Daskal resigned from his position as the Company’s Executive Vice-President, Chief Financial Officer and the Company’s principal financial officer in order to pursue other opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000005/0000012208-24-000005-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice-President, Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"1ea1259240b8b922a38162c7c28b0c75ef4e083f","claim":"BIO-RAD LABORATORIES, INC. entered into Revolving Credit Agreement with Wells Fargo Bank, National Association, as agent valued at $200,000,000 (effective 2024-02-13).","evidence_excerpt":"Bio-Rad Laboratories, Inc. (the “Company”) entered into a Credit Agreement dated as of February 13, 2024 (the “Revolving Credit Agreement”), by and among the Company, Bio-Rad Europe GmbH, Bio-Rad IHC Europe GmbH and Bio-Rad Laboratories (Singapore) Pte Ltd (collectively, the “Borrowers”), the lenders referred to therein, and Wells Fargo Bank, National Association, as agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000005/0000012208-24-000005-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Wells Fargo Bank, National Association, as agent"},{"label":"Value","value":"$200,000,000"},{"label":"Effective","value":"2024-02-13"}],"fact_type":"material_agreement"},{"claim_id":"536e2a86cbd7619fec452f20d63178eb3753c026","claim":"BIO-RAD LABORATORIES, INC. terminated Previous Revolving Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A., HSBC Bank USA, National Association, and MUFG Bank, Ltd. as co-syndication agents, and Citibank, N.A. and Wells Fargo Bank, National Association as co-documentation agents (effective 2024-02-14).","evidence_excerpt":"The Company repaid in full all outstanding obligations under the Previous Revolving Credit Agreement on February 14, 2024 and terminated all commitments thereunder.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000005/0000012208-24-000005-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A., HSBC Bank USA, National Association, and MUFG Bank, Ltd. as co-syndication agents, and Citibank, N.A. and Wells Fargo Bank, National Association as co-documentation agents"},{"label":"Effective","value":"2024-02-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}